Will biosimilars finally put a noticeable dent in sales of big pharma's blockbuster biologics or not? As if drug-pricing pressures in general weren't enough of a challenge, Johnson & Johnson said in its second quarter earnings report that a biosimilar for Remicade (infliximab) and payer demands for discounts contributed to a 13.9% decline in the product's US sales, although management stressed that the impact from biosimilars was still less than had been expected.
[Sidebar#SC099159]








